Alnylam Pharmaceuticals Inc.

138.88-0.1400-0.10%Vol 766.57K1Y Perf 8.60%
Apr 16th, 2021 16:00 DELAYED
BID135.54 ASK0.0000
Open139.59 Previous Close139.02
Pre-Market- After-Market138.88
 - -  - -%
Target Price
173.32 
Analyst Rating
Moderate Buy 1.71
Potential %
24.80 
Finscreener Ranking
★★★     50.22
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.97
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     56.09
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap16.29B 
Earnings Rating
Buy
Price Range Ratio 52W %
33.14 
Earnings Date
29th Apr 2021

Today's Price Range

137.38140.06

52W Range

119.29178.41

5 Year PE Ratio Range

-11.10-16.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.47%
1 Month
-4.32%
3 Months
-16.52%
6 Months
-4.48%
1 Year
8.60%
3 Years
41.21%
5 Years
101.89%
10 Years
1 343.66%

TickerPriceChg.Chg.%
ALNY138.88-0.1400-0.10
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
3.40
3.60
0.32
0.51
-9.10
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
84.20
-156.50
-141.40
-596.60
-
RevenueValueIndustryS&P 500US Markets
393.38M
3.35
83.75
69.39
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.93-2.09-8.29
Q03 2020-1.75-2.18-24.57
Q02 2020-1.82-1.5614.29
Q01 2020-1.89-1.6214.29
Q04 2019-2.25-2.47-9.78
Q03 2019-2.17-1.9211.52
Q02 2019-2.06-2.021.94
Q01 2019-2.20-1.7321.36
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.732.81Positive
6/2021 QR-1.624.71Positive
12/2021 FY-6.32-2.10Negative
12/2022 FY-3.97-13.43Negative
Next Report Date29th Apr 2021
Estimated EPS Next Report-1.73
Estimates Count9
EPS Growth Next 5 Years %-
Volume Overview
Volume766.57K
Shares Outstanding117.32M
Trades Count11.26K
Dollar Volume72.52M
Avg. Volume674.72K
Avg. Weekly Volume484.54K
Avg. Monthly Volume466.53K
Avg. Quarterly Volume606.18K

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 138.88 per share at the end of the most recent trading day (a -0.1% change compared to the prior day closing price) with a volume of 768.38K shares and market capitalization of 16.29B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.

The one-year performance of Alnylam Pharmaceuticals Inc. stock is 8.6%, while year-to-date (YTD) performance is 6.86%. ALNY stock has a five-year performance of 101.89%. Its 52-week range is between 119.29 and 178.41, which gives ALNY stock a 52-week price range ratio of 33.14%

Alnylam Pharmaceuticals Inc. currently has a PE ratio of -19.10, a price-to-book (PB) ratio of 16.45, a price-to-sale (PS) ratio of 40.27, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.54%, a ROC of -52.31% and a ROE of -66.47%. The company’s profit margin is -%, its EBITDA margin is -141.40%, and its revenue ttm is $393.38 Million , which makes it $3.35 revenue per share.

Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.73 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Moderate Buy (1.71), with a target price of $173.32, which is +24.80% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alnylam Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.67, ATR14 : 6.96, CCI20 : -5.54, Chaikin Money Flow : 0.01, MACD : -4.56, Money Flow Index : 42.40, ROC : 2.78, RSI : 41.42, STOCH (14,3) : 57.10, STOCH RSI : 0.97, UO : 42.38, Williams %R : -42.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $1 009 565), Akshay K. Vaishnaw (Sold 23 912 shares of value $3 358 416 ), Barry E. Greene (Option Excercise at a value of $1 163 880), Barry E. Greene (Sold 89 060 shares of value $12 389 297 ), John M. Maraganore (Option Excercise at a value of $1 194 507), John M. Maraganore (Sold 138 274 shares of value $19 035 968 ), Laurie B. Keating (Option Excercise at a value of $5 722 504), Laurie B. Keating (Sold 81 976 shares of value $13 025 838 ), Phillip A. Sharp (Option Excercise at a value of $279 000), Phillip A. Sharp (Sold 30 000 shares of value $3 746 748 ), Steven M. Paul (Option Excercise at a value of $139 500), Steven M. Paul (Sold 15 000 shares of value $2 100 000 ), Yvonne Greenstreet (Option Excercise at a value of $16 662 719), Yvonne Greenstreet (Sold 234 497 shares of value $36 325 955 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (63.16 %)
12 (66.67 %)
11 (78.57 %)
Moderate Buy
2 (10.53 %)
2 (11.11 %)
1 (7.14 %)
Hold
4 (21.05 %)
3 (16.67 %)
1 (7.14 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.26 %)
1 (5.56 %)
1 (7.14 %)
Summary RatingModerate Buy
1.71
Moderate Buy
1.64
Strong Buy
1.46

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

CEO: John M. Maraganore

Telephone: +1 617 551-8200

Address: 675 West Kendall Street, Cambridge 02142, MA, US

Number of employees: 1 453

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

News

Stocktwits